IV Fluids and Post-ERCP Pancreatitis

ERCP Clinical Trial

Official title:

Association Between Peri-procedural Intravenous Hydration and Post- Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05211206
• Other study ID #: REB21-1885
• Status: Recruiting
• Start date: January 10, 2022
• Est. completion date: February 28, 2026

Study information

• Verified date: December 2023
• Source: University of Calgary
• Contact: Nauzer Forbes, MD MSc
• Phone: 403-592-5089
• Email: nauzer.forbes[@]ucalgary.ca
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Aggressive intravenous hydration has been shown in randomized trials to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), though studied regimens are often impractical. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP. In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).

Description:

1. Background and Rationale

While very effective, endoscopic retrograde cholangiopancreatography (ERCP) is widely known to have the highest adverse event (AE) profile among all commonly performed endoscopic procedures, with a collective AE rate of >10%. Common AEs include post-ERCP pancreatitis (PEP), bleeding, cholangitis, cholecystitis, perforation, and cardiopulmonary events. PEP is the most common, with estimated rates of 5-10%. It is noteworthy that both the incidence of PEP and its associated mortality are rising.

It is of critical priority to patients, practitioners, and health administrators to investigate factors associated with all AEs and unplanned healthcare encounters (UHEs) following ERCP, especially given that most ERCPs are performed on an outpatient basis. The per-admission costs of post-ERCP UHEs are substantial, exceeding $10,000 and $70,000 for pancreatitis and cholangitis, respectively. PEP alone accounts for an estimated $200+ million in annual healthcare spending in the United States. Thus, researchers must prioritize the study of ERCP outcomes, striving to both identify and modify factors leading to AEs and UHEs.

Peri-procedural fluid management and its relationship with ERCP outcomes also remains incompletely understood. Aggressive intravenous hydration (AH) has been shown to reduce the risk of PEP compared with standard peri-procedural hydration regimens. However, all AH regimens studied to date involve continuous hydration for 8-24 hours, which is impractical and thus non-generalizable to almost all North American outpatient ERCPs practices. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP.

2. Research Question and Objectives

In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).

3. Methods

Design: This is a retrospective cohort study where all data used to answer the proposed research question will be obtained from research data previously collected under REB18-0410. REB18-0410 (CReATE) is a multicenter prospective cohort study that recruits patients undergoing ERCP during which various relevant clinical and patient demographic data have been collected. The objective of REB18-0410 is to determine the clinical effectiveness and adverse event profile of ERCP.

The exposure variable for this study will be a the total peri-procedural IV fluid volume administered, measured and reported as a continuous variable. In addition to these variables, other parameters we will assess include: the presence and timing of pharmacologic PEP prophylaxis, extent and timing of trainee involvement, the number and timing of common bile duct (CBD) cannulation attempts, the depth, timing, trajectory and number of PD cannulation(s), the presence and extent of PD opacification, the size(s) of sphincterotomy and/or sphincteroplasty, intra-procedural pathology, and the composition, caliber and length of any PD or CBD stent(s).

Outcomes: The primary outcome will be PEP, using established definitions. Secondary outcomes (defined a priori) will include PEP severity, overall and specific AEs (bleeding, cholangitis, cardio-pulmonary events), cannulation time and success rate, as well as overall procedure time and success rate.

Sample Size and Power: Using a cutoff of a total peri-procedural IV fluid volume of ≥ 2 L (versus < 1 L), a minimum of 1,530 patients are anticipated to meet the exposure definition, with an anticipated 12,750 patients that will meet the control definition. We will be able to demonstrate increases in PEP risk from 5.0% to 6.8% (a relative increase of 36%) with 82.3% power or from 5.0% to 7.0% (a relative increase of 40%) with 88.6% power.

Statistical Analysis: Variables will be compared using Student's t-test for measured variables and chi-squared test for categorical variables. P values < 0.05 will be considered significant. We will use multivariable logistic regression to assess associations between risk factors and having PEP versus not having PEP. Clinically relevant subgroup analyses will also be performed by relevant patient-, endoscopist-, and procedure-related characteristics. Odds ratios per outcome will be reported with 95% CIs.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 13000
• Est. completion date: February 28, 2026
• Est. primary completion date: December 31, 2025
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject referred for ERCP, regardless of indication;

• Subject age 18 years or older;

• Subject able to give informed consent to involvement be included.

Exclusion Criteria:

• Subject has a standard contraindication to ERCP;

• Subject or surrogate unable or unwilling to provide informed consent;

• Subject age < 18 years.

Related Conditions & MeSH terms

• ERCP
• Pancreatitis

Intervention

Other:
• IV fluids
Amount of intravenous fluids delivered

Locations

Country	Name	City	State
Canada	Peter Lougheed Hospital	Calgary	Alberta

Sponsors (6)

Lead Sponsor	Collaborator
University of Calgary	Halton Health (Oakville), Island Health, Victoria, BC, McGill University, Queen's University, University of Ottawa

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	post-ERCP pancreatitis	Number of participants with any 2 of: (1) epigastric abdominal pain, (2) serum amylase/lipase >3x the upper limit of normal, (3) imaging findings consistent with acute pancreatitis	30 days